Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;35(6):468-471.
doi: 10.5021/ad.22.108.

Upregulation of AKR1C3 in Sodium Butyrate Treated G361 Cell

Yoon Jin Lee  1   2 , Yu Sung Choi  3 , Sooyoung Kim  3 , Jae Young Heo  3 , Dong Sung Kim  3 , Moon Kyun Cho  4
Affiliations

Upregulation of AKR1C3 in Sodium Butyrate Treated G361 Cell

Yoon Jin Lee et al. Ann Dermatol. 2023 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have nothing to disclose.

Figures

Fig. 1
Fig. 1. AKR1C3 was downregulated in melanoma tissue, and upregulated following sodium butyrate. (A) The expression of AKR1C3 was almost decreased in melanoma but was significantly increased in normal human skin tissues. The relative protein expression of AKR1C3 according to the Mann–Whitney U-test was analyzed. (B) Representative immunohistochemistry (IHC) staining for AKR1C3 protein expression in paraffin-embedded melanoma and normal skin tissue. Weakly positive staining of AKR1C3 in melanoma (IHC stain, ×200). Strongly positive staining of AKR1C3 in normal skin (IHC stain, ×200). (C) AKR1C3 was expressed in SK-MEL24 and Hela, but almost decreased in G361. (D) The percentage of viable G361 cells was measured by MTT assay. (E) AKR1C3 expression in G361 cells was upregulaged following sodium butyrate treatment (0, 80, 160, 320, 640, and 1,280 µM). (F) ΔΨm was measured by staining the cells with 30 nM of Rhodamine-123. (G) Cellular ROS levels were measured by staining the cells with DCF-DA (10 µM). DCF-DA: 2′,7′-dichlorodihydrofuorescein diacetate.
See this image and copyright information in PMC

References

    1. Lin HK, Steckelbroeck S, Fung KM, Jones AN, Penning TM. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids. 2004;69:795–801. - PubMed
    1. Zakharov V, Lin HK, Azzarello J, McMeekin S, Moore KN, Penning TM, et al. Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma. Int J Clin Exp Pathol. 2010;3:608–617. - PMC - PubMed
    1. Miller VL, Lin HK, Murugan P, Fan M, Penning TM, Brame LS, et al. Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma. Int J Clin Exp Pathol. 2012;5:278–289. - PMC - PubMed
    1. Frycz BA, Murawa D, Borejsza-Wysocki M, Wichtowski M, Spychała A, Marciniak R, et al. Transcript level of AKR1C3 is downregulated in gastric cancer. Biochem Cell Biol. 2016;94:138–146. - PubMed
    1. Azzarello JT, Lin HK, Gherezghiher A, Zakharov V, Yu Z, Kropp BP, et al. Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms’ tumor. Int J Clin Exp Pathol. 2009;3:147–155. - PMC - PubMed

LinkOut - more resources